Open AccessEfficacy and safety of tofacitinib for treatment of rheumatoid arthritis
Author(s) -
Lisa M. Lundquist,
Sabrina Cole,
Martha L. Sikes
Publication year - 2014
Publication title -
world journal of orthopedics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.76
H-Index - 43
ISSN - 2218-5836
DOI - 10.5312/wjo.v5.i4.504
Subject(s) - tofacitinib , medicine , rheumatoid arthritis , janus kinase inhibitor , janus kinase , methotrexate , pharmacology , cytokine , clinical trial , cytokine receptor , arthritis , immunology
Tofacitinib is the first in a new class of nonbiologic disease-modifying antirheumatic drugs (DMARDs), a targeted, synthetic DMARD, approved for the treatment of rheumatoid arthritis (RA) as monotherapy or in combination with methotrexate or other non-biologic DMARD. Tofacitinib, an orally administered Janus kinase (JAK) inhibitor, decreases T-cell activation, pro-inflammatory cytokine production, and cytokine signaling by inhibiting binding of type I cytokine receptors family and γ-chain cytokines to paired JAK1/JAK3 receptors. The net effect of tofacitinb's mechanism of action is decreased synovial inflammation and structural joint damage in RA patients. To date, six phase 3 trials have been conducted to evaluate the safety and efficacy of tofacitinib under the oral rheumatoid arthritis triaLs (ORAL) series. This review describes the pharmacology of the novel agent, tofacitinib, and details the safety and efficacy data of the ORAL trials.